MedTrace Logo

ECMOsorb Trial - Impact of a VA-ECMO in Combination With CytoSorb in Critically Ill Patients With Cardiogenic Shock

NCT05027529 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2026-02-04

No results posted yet for this study

Summary

In the ECMOsorb study the impact of a veno-arterial -ECMO in combination with an extracorporeal cytokine hemadsorption system in critically ill patients with cardiogenic shock is to be examined

Conditions

  • Cardiogenic Shock

Interventions

DEVICE

CytoSorb

An extracorporeal cytokine hemoadsorption system is integrated in the VA-ECMO circuit

OTHER

VA-ECMO only

only VA-ECMO; NO extracorporeal cytokine hemoadsorption system is added

Sponsors & Collaborators

  • Christian Schulze

    lead OTHER

Principal Investigators

  • Christian Schulze, Prof. · Jena University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-21
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05027529 on ClinicalTrials.gov